SG11202009906TA - Pladienolide compounds and their use - Google Patents

Pladienolide compounds and their use

Info

Publication number
SG11202009906TA
SG11202009906TA SG11202009906TA SG11202009906TA SG11202009906TA SG 11202009906T A SG11202009906T A SG 11202009906TA SG 11202009906T A SG11202009906T A SG 11202009906TA SG 11202009906T A SG11202009906T A SG 11202009906TA SG 11202009906T A SG11202009906T A SG 11202009906TA
Authority
SG
Singapore
Prior art keywords
pladienolide
compounds
pladienolide compounds
Prior art date
Application number
SG11202009906TA
Other languages
English (en)
Inventor
Gregg F Keaney
John Wang
Baudouin Gerard
Kenzo Arai
Xiang Liu
Guo Zhu Zheng
Kazunobu Kira
Lisa A Marcaurelle
Marta Nevalainen
Ming-Hong Hao
Morgan Welzel O'shea
Parcharee Tivitmahaisoon
Sudeep Prajapati
Touping Luo
Nicholas C Gearhart
Jason T Lowe
Yoshihiko Kotake
Satoshi Nagao
Sonobe Regina Mikie Kanada
Masayuki Miyano
Norio Murai
Andrew Cook
Shelby Ellery
Atsushi Endo
James Palacino
Dominic Reynolds
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of SG11202009906TA publication Critical patent/SG11202009906TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyrane Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202009906TA 2018-04-09 2019-04-08 Pladienolide compounds and their use SG11202009906TA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862655021P 2018-04-09 2018-04-09
US201862679653P 2018-06-01 2018-06-01
US201962814843P 2019-03-06 2019-03-06
US201962814838P 2019-03-06 2019-03-06
PCT/US2019/026313 WO2019199667A2 (fr) 2018-04-09 2019-04-08 Certains composés de pladiénolide et procédés d'utilisation

Publications (1)

Publication Number Publication Date
SG11202009906TA true SG11202009906TA (en) 2020-11-27

Family

ID=66248768

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202009906TA SG11202009906TA (en) 2018-04-09 2019-04-08 Pladienolide compounds and their use

Country Status (18)

Country Link
US (1) US11926619B2 (fr)
EP (1) EP3774759A2 (fr)
JP (2) JP7335265B2 (fr)
KR (1) KR20210006907A (fr)
CN (1) CN113166091A (fr)
AU (1) AU2019251096B2 (fr)
BR (1) BR112020020792A2 (fr)
CA (1) CA3096400A1 (fr)
CL (3) CL2020002604A1 (fr)
CO (1) CO2020013834A2 (fr)
IL (3) IL303335B1 (fr)
JO (2) JOP20200243A1 (fr)
MX (3) MX2020010606A (fr)
PE (1) PE20212327A1 (fr)
PH (1) PH12020500666A1 (fr)
SG (1) SG11202009906TA (fr)
TW (1) TW201945351A (fr)
WO (1) WO2019199667A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR122546A1 (es) * 2020-06-05 2022-09-21 Eisai R&D Man Co Ltd Conjugados de anticuerpo anti bcma-fármaco y métodos de uso
US20240043928A1 (en) 2020-11-04 2024-02-08 Eisai R&D Management Co., Ltd. Biomarkers for myelodysplastic syndrome (mds) and methods of using the same
WO2023131866A1 (fr) 2022-01-05 2023-07-13 Eisai R&D Management Co., Ltd. Biomarqueurs pour le syndrome myélodysplasique (mds) et leurs méthodes d'utilisation
CN115414351B (zh) * 2022-09-19 2024-05-17 山东大学齐鲁医院 pladienolide B与PD-L1抗体组合在肿瘤免疫治疗领域的应用
WO2024101298A1 (fr) * 2022-11-07 2024-05-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 Procédé de production d'un composé macrolide

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
EP0859959B1 (fr) 1995-11-10 2003-08-06 ELAN CORPORATION, Plc Peptides favorisant le transport dans les tissus et procedes d'identification et d'utilisation correspondants
AU784012B2 (en) 1999-08-24 2006-01-12 E. R. Squibb & Sons, L.L.C. Human CTLA-4 antibodies and their uses
TWI312681B (en) * 2001-02-01 2009-08-01 Novel physiologically active substance
TWI334866B (en) 2002-05-29 2010-12-21 Mercian Corp Novel physiologically active substances
CN1671856B (zh) 2002-07-31 2010-05-12 卫材R&D管理株式会社 生理活性物质
EP1541570A4 (fr) 2002-07-31 2008-05-21 Mercian Corp Nouvelle substance active sur le plan physiologique
AU2003285012A1 (en) 2002-10-24 2004-05-13 Sepracor, Inc. Compositions comprising zopiclone derivatives and methods of making and using the same
NZ540103A (en) 2002-11-29 2007-05-31 Mercian Corp Process for producing macrolide compound
KR20060110865A (ko) 2003-11-27 2006-10-25 에자이 가부시키가이샤 매크로라이드계 화합물의 수산화에 관여하는 ｄｎａ
EP1712642B1 (fr) 2004-02-06 2010-06-02 Eisai R&D Management Co., Ltd. Procede d examen de la sensibilite d une cellule cancer euse a un agent anticancereux
JP4599357B2 (ja) 2004-07-20 2010-12-15 エーザイ・アール・アンド・ディー・マネジメント株式会社 プラジエノライドの生合成に関与するポリペプチドをコードするｄｎａ
WO2007110705A2 (fr) 2005-09-28 2007-10-04 Novimmune Sa Compositions macrolides en tant qu'agents thérapeutiques
WO2007110704A2 (fr) 2005-09-28 2007-10-04 Novimmune Sa Compositions macrolides en tant qu'agents thérapeutiques
EP1935893A4 (fr) 2005-10-13 2009-07-22 Eisai R&D Man Co Ltd Synthèse totale de pladienolide b et de pladienolide d
WO2008020584A1 (fr) 2006-08-14 2008-02-21 Eisai R & D Management Co., Ltd. Préparation lyophilisée stable
US7790887B2 (en) 2007-01-29 2010-09-07 Eisai R&D Management Co., Ltd. Macrolide compound in solid form, process for preparation thereof, and pharmaceutical composition containing the same
US20080312317A1 (en) 2007-04-12 2008-12-18 Eisai R&D Management Co., Ltd. 12 membered-ring macrolactam derivatives
CN101730693A (zh) * 2007-07-06 2010-06-09 卫材R&D管理有限公司 大环内酯系化合物的制造方法及其制造中间体
WO2013148324A1 (fr) 2012-03-26 2013-10-03 The Regents Of The University Of California Composés de polycétides anticancéreux
MX368507B (es) 2012-05-15 2019-10-07 Bristol Myers Squibb Co Uso de un anticuerpo anti-pd-1 en combinación con un anticuerpo anti-ctla-4 en la manufactura de un medicamento para el tratamiento de cáncer.
US20140275010A1 (en) 2013-03-12 2014-09-18 Guo Zhu Zheng Quaternary salts
SG11201609693XA (en) * 2014-05-15 2016-12-29 Eisai R&D Man Co Ltd Pladienolide pyridine compounds and methods of use
SG11201700207WA (en) 2014-07-11 2017-02-27 Genentech Inc Anti-pd-l1 antibodies and diagnostic uses thereof
EP3910073B1 (fr) 2015-09-01 2024-03-06 Eisai R&D Management Co., Ltd. Variants d'épissage associés à des mutants de sf3b1 néomorphes
MX2018006155A (es) 2015-11-18 2018-08-01 Eisai R&D Man Co Ltd Una forma en estado solido de compuestos de pladienolida piridina y metodos de uso.
AU2019279012A1 (en) 2018-06-01 2020-12-24 Eisai R&D Management Co., Ltd. Methods of using splicing modulators

Also Published As

Publication number Publication date
CN113166091A (zh) 2021-07-23
CO2020013834A2 (es) 2020-12-10
IL277749A (en) 2020-11-30
BR112020020792A2 (pt) 2021-01-12
PE20212327A1 (es) 2021-12-14
MX2023009976A (es) 2023-10-30
IL312725A (en) 2024-07-01
IL303335A (en) 2023-07-01
CA3096400A1 (fr) 2019-10-17
JP2021521124A (ja) 2021-08-26
IL303335B1 (en) 2024-09-01
KR20210006907A (ko) 2021-01-19
IL277749B2 (en) 2023-11-01
CL2022000458A1 (es) 2022-10-21
WO2019199667A2 (fr) 2019-10-17
JOP20200243A1 (ar) 2020-09-29
US20210163456A1 (en) 2021-06-03
AU2019251096A1 (en) 2020-11-26
MX2020010606A (es) 2021-01-15
AU2019251096B2 (en) 2023-04-20
TW201945351A (zh) 2019-12-01
CL2020002604A1 (es) 2021-01-15
JP2023156456A (ja) 2023-10-24
MX2022015216A (es) 2023-01-04
CL2023002549A1 (es) 2024-01-26
IL277749B1 (en) 2023-07-01
WO2019199667A3 (fr) 2019-11-21
PH12020500666A1 (en) 2021-07-26
AU2023202358A1 (en) 2023-05-18
EP3774759A2 (fr) 2021-02-17
JP7335265B2 (ja) 2023-08-29
US11926619B2 (en) 2024-03-12
JOP20200242A1 (ar) 2020-09-29

Similar Documents

Publication Publication Date Title
IL264258B (en) Diazahetero-bicyclic substituted compounds and their use
GB201803568D0 (en) Novel compounds and uses
EP3826721C0 (fr) Composés de naphtyridine et leurs utilisations
IL277749A (en) Palladianolide compounds and their use
IL284514A (en) Halo-allylamine compounds and their use
IL277502A (en) Compounds and uses for them
IL292488B1 (en) Pyridineamine-pyridone and pyrimidineamine-pyridone compounds
GB201807286D0 (en) New use
IL269836B (en) Converted N-arylethyl-2-aminoquinoline-4-carboxamides and their use
IL280644A (en) Magnesium serine compound and its use
IL279483A (en) Cyanotriazole compounds and their uses
IL282526A (en) 5-Azaindazole history and their use
IL282527A (en) 5-Azaindazole history and their use
GB201812078D0 (en) Novel compounds and their uses
GB201700404D0 (en) Compounds and composistions
GB201813312D0 (en) Compounds and their therapeutic use
GB201801102D0 (en) New compounds and uses
IL292482B2 (en) Azaindolylpyridone and diazaindolylpyridone compounds
IL280369A (en) Myokines and their uses
IL269843B (en) Converted N-arylethyl-2-arylquinoline-4-carboxamides and their use
GB201906914D0 (en) Substituted naphtahlene diimdes and their use
GB201806349D0 (en) New compounds and uses
IL283540A (en) Dock1 inhibitory compound and use thereof
GB201813311D0 (en) Novel compounds and their use
GB201810667D0 (en) New compounds and uses